Simulation in drug development: good practices

Nicholas HG Holford, M Hale, HC Ko, JL Steimer, LB Sheiner, CC Peck, P Bonate, WR Gillespie, T Ludden, DB Rubin, D Stanski

1999-07-01

Abstract:With the rapidly changing health care and research environments, it has become essential that the drug development process achieve greater efficiency, cost-effectiveness and timeliness. A major component of drug development is drug testing in human for safety and efficacy. Past approaches to clinical drug development often resulted in much of the human clinical trials information being considered less than maximally informative, providing results which did not add new information that was relevant to the drug development and the approval process (Peck 1997).Simulation of clinical trials has recently gained attention as an emerging technique for knowledge synthesis and exploration of possible clinical trial results based upon a mathematical/stochastic model of the trial, including sub-models of the drug action and disease process ( Hale et al. 1996, Peck & Desjardins 1996, ECPM 1996, CDDS 1997, FDA 1999, Peck 1997b, Krall et al. 1998). The basic rationale for computer simulation has existed for many years and the technique has been successfully used in several scientific and industrial application areas ( Johnson 1998). The application of simulation in the domain of pharmaceutical medicine, clinical pharmacology and drug development has been largely restricted in the past to evaluation of statistical methodology and forecasting of individual or population pharmacokinetics. It is proposed that simulation has a much broader potential to aid in the clinical development, regulatory review, commercialization, and medical application process. As described in detail later, models will incorporate elements associated with the drug, the disease …